Si3N4

Quote

anonymous said:
Who cares about ceramic??? That cup position is no good either in that x Ray. Lots of reasons for it to fail...... When an article says "it appears" you know it's full of shit. This was a poorly put together piece.
Click to expand...


Uhh isn't ZTA the top selling femoral head on market? I'm pretty sure Zimmer sells them...who cares about that right?

Oh all scientific articles use that language...at least the ones I've read.
 

anonymous said:
Since you want to talk stock so badly then amedica is extremely undervalued given its products both current and pending + addressable market size.
With their new sales team and partnerships with Zimmer & Kyocera its a matter of time.
Click to expand...

https://finnewsweek.com/amedica-corp-amda-shares-move-1-21/280797/

Look at your 5 year history, your 1 year history ect ect. Amedica is valued right where it should be... A Penny Stock. When a company over values itself from the start this is what you get.
 
anonymous said:
Since you want to talk stock so badly then amedica is extremely undervalued given its products both current and pending + addressable market size.
With their new sales team and partnerships with Zimmer & Kyocera its a matter of time.
Click to expand...


Just research the tech, its potential, and Amedicas long relationship with Zimmer. You'll see the true value here.

Zimmer acquired Implex for $225 million 2003, just to show how undervalued Amedica is. Markets easily 3x the size it was in 2003 & Valeo is cleared in more markets+pending China & Japan.
 
Zimmer Biomet Inc.’s Primagen autograft substitute is the device’s most direct competitor. (See Medical Device Daily, Dec. 15, 2016.) Zimmer Biomet said Primagen offers a combination of demineralized cortical bone fibers with verified osteoinductivity and cancellous bone, providing a trabecular structure for natural bony in-growth with optimal handling and delivery characteristics.
Primagen is moldable and delivered via a syringe rather than being a solid implant like Amedica’s. It is indicated for use beyond the spine, and may be used in the repair, replacement, reconstruction or supplementation of tissue in other musculoskeletal defects.

Zimmer competing against themselves is great news for everyone else.
 
anonymous said:
https://finnewsweek.com/amedica-corp-amda-shares-move-1-21/280797/

Look at your 5 year history, your 1 year history ect ect. Amedica is valued right where it should be... A Penny Stock. When a company over values itself from the start this is what you get.
Click to expand...

^^^THIS^^^
Amedica was so over valued from the start, hoping they would get bought years ago. Now we are here and they are getting by on scraps. Eventually they will be purchased for pennies on the dollar and absorbed.
 
anonymous said:
Zimmer Biomet Inc.’s Primagen autograft substitute is the device’s most direct competitor. (See Medical Device Daily, Dec. 15, 2016.) Zimmer Biomet said Primagen offers a combination of demineralized cortical bone fibers with verified osteoinductivity and cancellous bone, providing a trabecular structure for natural bony in-growth with optimal handling and delivery characteristics.
Primagen is moldable and delivered via a syringe rather than being a solid implant like Amedica’s. It is indicated for use beyond the spine, and may be used in the repair, replacement, reconstruction or supplementation of tissue in other musculoskeletal defects.

Zimmer competing against themselves is great news for everyone else.
Click to expand...

You do understand that primagen is used in combination with devices like Ardis right? A Si3N4 version of Ardis would still require primagen.

If you are comparing primagen to Amedicas CsC all porous insert into an interbody device then yes those would be competing products not unlike a Iphone 7S & Iphone 7 compete.

An all porous implant is likely Zimmers goal and since Si3N4 fuses clinically as well as Autograft why would anyone want primagen? Not sure when this device would be cleared to market in US.

2nd generation Si3N4 shows significantly better results than 1st gen. Be interesting to see the in vivo data.
 
The other pearl is with femoral heads. Better than ceramic, and a dog in the fight against Oxinium. Maybe M-O-M potential? I bought stock years ago, but it has let me down. I still believe in product, but it is undervalued.
 
anonymous said:
In November 2016, Amedica said the FDA declined to award 510(k) clearance for Valeo C+CsC, a cancellous structured ceramic (CsC) cervical implant made of porous silicon nitride and intended for spinal fusion procedures. This is designed to encourage the patient’s own bone to grow into the porous structure, knitting together in the manner of broken bones. Amedica claims that it is the world’s first structural porous bioceramic – it is CE marked and on sale in Europe.
The FDA’s rejection was by no means the start of Amedica’s troubles. Just a month earlier, it had made nearly 40% of its staff redundant to save around $2m in annual operating costs. But the company has been performing poorly for much longer than that.
Its $20m Nasdaq IPO in February 2014 – at the very beginning of that year’s sudden medtech IPO boom – was little short of a disaster. Before floating, Amedica lowered its projected price range from $10-12 down to $8-10, but eventually priced at just $5.75. A slow and steady decline followed, and over the course of 2014, the stock had slipped 86%.

AMEDICA IS A DISASTER.
Click to expand...

This is a board to discuss the products/sales etc...

If you are hedge fund managers or Market Makers that trying to come here spread your lies about the stock with superior tech that is about to be owned by Zimmer. Please go to this two links below to bash/ talk crap about the stock:

https://investorshub.advfn.com/Amedica-Corp-AMDA-27931/

https://investorshub.advfn.com/Zimmer-Biomet-Holdings-Inc-ZBH-25435/
 
anonymous said:
This is a board to discuss the products/sales etc...

If you are hedge fund managers or Market Makers that trying to come here spread your lies about the stock with superior tech that is about to be owned by Zimmer. Please go to this two links below to bash/ talk crap about the stock: /
Click to expand...

Ouch. Truth hurts because this is from amedicas own mouth about FDA issues and even their response to Stock market troubles. This is the Zimmer forum not the amedica forum. You post bullshit and then try to bash or silence the truth and everyone sees right through you. If you only knew what people at Zimmer say about amedica as a company, regardless of what products you are trying to make. From your grand fail entrance to begging for business on online forums. This gets better everyday.
 
anonymous said:
All signs point to hiding information with this.
Click to expand...

Long-lived Asset audit often done before M&A. IR for Amedica is being handled by a securities lawyer with M&A experience.
Dana Lyons has Merger experience aiding in the integration of Zimmer & Biomet.
Ryan Long job is Director of Strategic Development. Part of the duty for this individual has to do with establishing partnerships with other companies, M&A, & other things like that.
 
anonymous said:
Ouch. Truth hurts because this is from amedicas own mouth about FDA issues and even their response to Stock market troubles. This is the Zimmer forum not the amedica forum. You post bullshit and then try to bash or silence the truth and everyone sees right through you. If you only knew what people at Zimmer say about amedica as a company, regardless of what products you are trying to make. From your grand fail entrance to begging for business on online forums. This gets better everyday.
Click to expand...

Your right this is Zimmers forum and the topic of discussion is Zimmers need of Si3N4...hence the title. Your bashing has brought in the stock to try to deviate the discussion away from the merits of ZB+A merger. As far as I see I it, ZB needs something new for Spine & Dental to grow revenues; Si3N4 fills that need...plus it gives Zimmer access to next gen hip/knee tech like its wanted since 2011.

What is ZB modus operandi? To acquire new technology through inorganic means of acquisition to grow it top line. With Amedicas partnerships with Weigao in China & Kyocera in Japan, that's precisely what Amedica would bring to Zimmer.
 
anonymous said:
Long-lived Asset audit often done before M&A. IR for Amedica is being handled by a securities lawyer with M&A experience.
Dana Lyons has Merger experience aiding in the integration of Zimmer & Biomet.
Ryan Long job is Director of Strategic Development. Part of the duty for this individual has to do with establishing partnerships with other companies, M&A, & other things like that.
Click to expand...
Lol at the "Audit". You have multiple problems here that were not corrected after allready having had 1 year to do it.
Ask the Securities and Exchange division what they need because they are pissed and you have no clue. Read below......

As previously disclosed, on August 17, 2016, Amedica Corporation (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The NASDAQ Stock Market LLC (“Nasdaq”) indicating that the bid price for the Company's common stock had closed below the minimum $1.00per share threshold for continued listing on The Nasdaq Capital, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”), for the prior 30 consecutive trading days. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was ultimately provided with two consecutive 180 calendar day periods to demonstrate compliance with the Bid Price Rule, which expired on August 14, 2017.
The Company did not regain compliance with the Bid Price Rule by August 14, 2017; accordingly, on August 22, 2017, the Company received notice from the Staff that based upon the Company's continued non-compliance with the Rule, the Company's securities would be subject to delisting from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearings Panel. The Company intends to timely request a hearing before the Panel, at which hearing it will present its plan to evidence compliance with all requirements for continued listing on The Nasdaq Capital Market. The Company's request for a hearing will stay any suspension/delisting action pending the outcome of the hearing and the expiration of any extension granted to the Company by the Panel.
The Staff's August 22, 2017 notice also indicated that, notwithstanding the extension previously granted by the Staff to the Company to file its delinquent periodic reports with the Securities and Exchange Commission, including the Form 10-K for the period ended December 31, 2016, and the Forms 10-Q for the periods ended March 31, 2017 and June 30, 2017, and thereby evidence compliance with Nasdaq Listing Rule 5250(c)(1) (the “Filing Rule”), the Company's non-compliance with the Filing Rule could serve as a separate basis for delisting and, as such, the Company should be prepared to address its plan to regain compliance with the Filing Rule at the hearing.
 
From Amedica 8-25-17
"The Company is diligently working to evidence compliance with all applicable requirements for continued listing on The Nasdaq Capital Market; however, there can be no assurance that the Panel will grant the Company's request for continued listing or that the Company will regain compliance with the applicable criteria within the period of time that may be granted by the Panel."

This wording alone shows how confident Amedica is in themselves. No wonder you are on an online forum with your desperation.
"or that the Company will regain compliance with the applicable criteria within the period of time that may be granted by the Panel."
 
The global bioactive materials market is expected to reach USD 3.29 billion by 2025, according to a new report by Grand View Research, Inc. The market is expected to witness a CAGR of 10.1% over the forecast period, owing to rising substitution of engineered plastics in implants.
Click to expand...

http://crweworld.com/newsroom/prnewswire?rkey=20170906enUK201709063369&filter=10284

Amedica has a bioactive coating product in development. Seems like another product that Zimmer could benefit from.
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2017027426
 


Write your reply...
Top Bottom
Back
Quote